Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Ralliant Corporation $RAL

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Ralliant by 129.1%, buying an additional 122,039 shares to hold 216,569 shares valued at about $11.05 million (≈0.19% ownership).
• Analyst sentiment is broadly positive with a MarketBeat consensus of "Moderate Buy" and a $50.50 target; several firms issued upgrades (e.g., Vertical to Buy) while others trimmed targets (Barclays $60→$52, Oppenheimer $60→$50).
• Insider activity included an SVP selling 5,485 shares at $45 and a director buying 1,250 shares at $39.97; Ralliant beat quarterly EPS estimates ($0.69 vs. $0.67), set FY2026 guidance of 2.22–2.42 EPS, and pays a quarterly dividend of $0.05 (≈0.4% yield).

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Ralliant Corporation (NYSE:RAL - Free Report) by 129.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 216,569 shares of the company's stock after buying an additional 122,039 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.19% of Ralliant worth $11,054,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Westfuller Advisors LLC purchased a new stake in shares of Ralliant in the 3rd quarter worth approximately $26,000. Palisade Asset Management LLC purchased a new stake in shares of Ralliant in the 3rd quarter worth approximately $26,000. V Square Quantitative Management LLC purchased a new stake in shares of Ralliant in the 4th quarter worth approximately $26,000. UMB Bank n.a. purchased a new stake in shares of Ralliant in the 3rd quarter worth approximately $29,000. Finally, BOKF NA purchased a new stake in shares of Ralliant in the 3rd quarter worth approximately $29,000.

Analyst Upgrades and Downgrades

Several brokerages have commented on RAL. Zacks Research upgraded Ralliant from a "strong sell" rating to a "hold" rating in a research note on Monday, April 13th. Vertical Research upgraded Ralliant from a "hold" rating to a "buy" rating and set a $45.00 price target on the stock in a research note on Friday, February 6th. Barclays cut their price objective on Ralliant from $60.00 to $52.00 and set an "overweight" rating for the company in a report on Monday, February 9th. Morgan Stanley reiterated an "overweight" rating and set a $45.00 price objective on shares of Ralliant in a research report on Friday, February 6th. Finally, Oppenheimer lowered their target price on Ralliant from $60.00 to $50.00 and set an "outperform" rating on the stock in a report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Ralliant currently has an average rating of "Moderate Buy" and a consensus target price of $50.50.

Insider Activity

In related news, SVP Karen M. Bick sold 5,485 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the completion of the transaction, the senior vice president directly owned 46,756 shares in the company, valued at approximately $2,104,020. The trade was a 10.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kevin E. Bryant bought 1,250 shares of Ralliant stock in a transaction that occurred on Friday, February 6th. The stock was purchased at an average cost of $39.97 per share, with a total value of $49,962.50. Following the completion of the acquisition, the director directly owned 4,653 shares in the company, valued at $185,980.41. This represents a 36.73% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders bought 8,145 shares of company stock worth $332,233.

Ralliant Stock Down 1.5%

RAL opened at $44.70 on Friday. The firm's 50 day simple moving average is $44.07 and its two-hundred day simple moving average is $46.85. The company has a market capitalization of $5.00 billion and a PE ratio of 22.81. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $57.02. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to analysts' expectations of $543.04 million. The business's revenue for the quarter was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS. As a group, equities analysts forecast that Ralliant Corporation will post 2.37 EPS for the current year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 23rd. Stockholders of record on Monday, March 9th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 9th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Ralliant's dividend payout ratio (DPR) is 10.20%.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.